COVID-19 pandemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Extensive efforts are underway to … Compounds in cannabis can prevent infection from the virus that causes Covid-19 by blocking its entry into cells, according to a study published this week by researchers affiliated with Oregon State University.
COVID-19 and Cannabidiol (CBD)
COVID-19 pandemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery. Cannabis products such as cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental health problems and substance use disorders. This commentary will briefly clear the myth that CBD can ameliorate a wide range of COVID-19 associated health effects including anxiety, depression, or any substance use disorder, and show that there is a clear lack of sufficient unbiased clinical evidence from well-designed double-blind, placebo-controlled clinical trials to prove the antianxiety or antidepression therapeutic properties of CBD and support its wide use as medicine to treat COVID-19- associated mental health conditions or substance use disorders. Finally, we suggest that addiction physicians must play an important role in dealing with their patients requesting CBD prescription for treating any of these conditions.
Copyright © 2020 American Society of Addiction Medicine.
Conflict of interest statement
Research grants to the institution from Merck, Inc., Gillead Sciences, and Airbutus pharmaceuticals. Other authors report no conflicts of interest.
Khalsa JH, Maggirwar SB, Bunt G. Khalsa JH, et al. J Neuroimmune Pharmacol. 2021 Dec;16(4):718-721. doi: 10.1007/s11481-021-10013-8. Epub 2021 Oct 16. J Neuroimmune Pharmacol. 2021. PMID: 34655372 Free PMC article.
Crippa JAS, Zuardi AW, Guimarães FS, Campos AC, de Lima Osório F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC; Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Crippa JAS, et al. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603. JAMA Netw Open. 2021. PMID: 34387679 Free PMC article.
Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. Wang B, et al. Aging (Albany NY). 2020 Nov 22;12(22):22425-22444. doi: 10.18632/aging.202225. Epub 2020 Nov 22. Aging (Albany NY). 2020. PMID: 33221759 Free PMC article.
Malinowska B, Baranowska-Kuczko M, Kicman A, Schlicker E. Malinowska B, et al. Int J Mol Sci. 2021 Feb 17;22(4):1986. doi: 10.3390/ijms22041986. Int J Mol Sci. 2021. PMID: 33671463 Free PMC article. Review.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Hong H, Sloan L, Saxena D, Scott DA. Hong H, et al. Biomedicines. 2022 Aug 12;10(8):1959. doi: 10.3390/biomedicines10081959. Biomedicines. 2022. PMID: 36009504 Free PMC article. Review.
Zhang Q, Melchert PW, Markowitz JS. Zhang Q, et al. Chem Biol Interact. 2022 Sep 25;365:110097. doi: 10.1016/j.cbi.2022.110097. Epub 2022 Aug 11. Chem Biol Interact. 2022. PMID: 35964681 Free PMC article.
Kumar S, Yelamanchili S, Seth P, Bidlack JM, Pendyala G, Maggirwar S, Chang SL. Kumar S, et al. J Neuroimmune Pharmacol. 2021 Dec;16(4):699-705. doi: 10.1007/s11481-021-10038-z. Epub 2021 Dec 22. J Neuroimmune Pharmacol. 2021. PMID: 34935110 Free PMC article.
Maggirwar SB, Khalsa JH. Maggirwar SB, et al. Viruses. 2021 Jun 9;13(6):1099. doi: 10.3390/v13061099. Viruses. 2021. PMID: 34207524 Free PMC article. Review.
Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. Rapin L, et al. J Cannabis Res. 2021 Jun 23;3(1):19. doi: 10.1186/s42238-021-00078-w. J Cannabis Res. 2021. PMID: 34162446 Free PMC article.
Study Finds Cannabis Compounds Prevent Infection By Covid-19 Virus
Compounds in cannabis can prevent infection from the virus that causes Covid-19 by blocking its entry into cells, according to a study published this week by researchers affiliated with Oregon State University. A report on the research, “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,” was published online on Monday by the Journal of Natural Products.
The researchers found that two cannabinoid acids commonly found in hemp varietals of cannabis, cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA, can bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19. By binding to the spike protein, the compounds can prevent the virus from entering cells and causing infection, potentially offering new avenues to prevent and treat the disease.
Compounds in cannabis can prevent infection by the virus that causes Covid-19, according to research . [+] published this week.
“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2,” the researchers wrote in an abstract of the study.
The study was led by Richard van Breemen, a researcher with Oregon State’s Global Hemp Innovation Center in the College of Pharmacy and Linus Pauling Institute, in collaboration with scientists at the Oregon Health & Science University. Van Breeman said that the cannabinoids studied are common and readily available.
“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said, as quoted by local media. “They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans.”
Best Travel Insurance Companies
Best Covid-19 Travel Insurance Plans
Cannabinoids Effective Against New Variants
Van Breemen added that CBDA and CBGA blocked the action of emerging variants of the virus that causes Covid-19, saying that “our research showed the hemp compounds were equally effective against variants of SARS-CoV-2, including variant B.1.1.7, which was first detected in the United Kingdom, and variant B.1.351, first detected in South Africa.”
CBGA and CBDA prevented infection from the virus that causes Covid-19 by binding to its . [+] characteristic spike protein.
The spike protein is the same part of the virus target by Covid-19 vaccines and antibody therapies. In addition to the spike protein, SARS-CoV-2 has three more structural proteins as well as 16 nonstructural proteins and several compounds van Breemen characterized as “accessory” proteins, all of which are potential targets for drugs developed to prevent Covid-19.
“Any part of the infection and replication cycle is a potential target for antiviral intervention, and the connection of the spike protein’s receptor binding domain to the human cell surface receptor ACE2 is a critical step in that cycle,” van Breeman said. “That means cell entry inhibitors, like the acids from hemp, could be used to prevent SARS-CoV-2 infection and also to shorten infections by preventing virus particles from infecting human cells. They bind to the spike proteins so those proteins can’t bind to the ACE2 enzyme, which is abundant on the outer membrane of endothelial cells in the lungs and other organs.”
Although further research is needed, van Breemen noted that study shows the cannabinoids could be developed into drugs to prevent or treat Covid-19.
“These compounds can be taken orally and have a long history of safe use in humans,” van Breemen noted. “They have the potential to prevent as well as treat infection by SARS-CoV-2. CBDA and CBGA are produced by the hemp plant as precursors to CBD and CBG, which are familiar to many consumers. However, they are different from the acids and are not contained in hemp products.”
Van Breeman also noted that the research showed the cannabinoids were effective against new variants of the virus, which he said are “one of the primary concerns” in the pandemic for health officials and clinicians.
“These variants are well known for evading antibodies against early lineage SARS-CoV-2, which is obviously concerning given that current vaccination strategies rely on the early lineage spike protein as an antigen,” said van Breemen. “Our data show CBDA and CBGA are effective against the two variants we looked at, and we hope that trend will extend to other existing and future variants.”
The researcher added that “resistant variants could still arise amid widespread use of cannabinoids but that the combination of vaccination and CBDA/CBGA treatment should make for a much more challenging environment for SARS-CoV-2.”